Patent Application
20130344043
The present invention relates to a method for enhancing PPARγ expression. In particular, the method comprises administering a subject in need thereof an effective amount of a specific strain.
Peroxisome proliferator-activated receptor (PPAR) is a member of the nuclear receptors (NR) superfamily, as well as a transcription factor regulated by hormones. Different from other hormone-activated receptors, PPAR is located in the cytoplasm and then transferred into nucleus after being bound by an activated ligand; and subsequently, the complex binds to DNA response elements to activate their downstream gene expression (Glass et al., Genes Dev (2000) 14, 121-141). PPAR is a typical receptor, activated by metabolites, and is located in the nucleus. There are three types of PPARs that have been identified as α, β/δ and γ, each of which binds to a retinoid-X-receptor (RXR) to form a heterodimer receptor. The main function of PPAR β/δ is to regulate the proliferation and differentiation of gut cells. PPARγ is expressed in adipocytes, skeletal muscle cells, osteoclasts, osteoblasts and some immune cells, and its function is similar to PPARα. It was reported that it is lethal, to the subject, to knock out the PPARγ gene. The human species only has four genotypes of PPARγ, but only expresses PPARG-1 and PPARG-2 proteins in normal cells. PPARG-1 proteins are expressed extensively in cells, while PPARG-2 proteins are mainly limited to adipocytes.
It was also reported that PPARγ, activated by ligands, increased ligand-unrelated transcription activity through phosphorylation (Diradourian et al., Biochimie (2005) 87, 33-38). It was demonstrated that not only did PPARγ function as a transcription factor, PPARγ also inhibited inflammation-related gene expression by sumoylation through ligand activation. It is concluded that the function of inflammation related genes expression inhibition depends on binding the sumoylated PPARγ protein and the DNA repressor complex with the inflammation related genes, thereby preventing the 19S proteasome from degrading the repressor (Pascual et al., Nature (2005)437, 759-763).
It was reported in animal and human trials that a PPARγ activator was effective in treating diabetes and also provided anti-inflammation uses. PPARγ agonist Rosiglitazone, a type of glucocorticoid, was found to be effective in treating asthma in murine model or human trial (Narala et al., Respir Res (2007) 8, 90). Dominant negative mutation of human PPARγ results in a stereotyped syndrome of partial lipodystrophy and insulin resistance (Semple et al., J. Clin. Invest. (2006) 116, 581-589). PPARγ agonist was also often used for treating type II diabetes, e.g. pioglitazone and Rosiglitazone. It was also found that PPARγ agonist was effective in reducing bone loss and inflammation in the rheumatoid arthritis rat model (Koufany et al., Arthritis Res Ther (2008) 10, R6; Doshi et al., Expert Opin. Investig. Drugs (2010) 19(4), 489-512). In clinical trials, Rosiglitazone was also found to be effective in treating lipodystrophy (Anghel et al., Cell Res (2007) 17, 486-511).
Therefore, a new approach for enhancing PPARγ expression is desirable.
It has been unexpectedly discovered that a specific strain, Lactobacillus gasseri PM-A0005, which was deposited under Budapest Treaty in the China Center for Type Culture Collection (CCTCC), China with Deposit No. M 207039, enhances PPARγ expression.
Therefore, in one aspect, the present invention provides a method for enhancing PPARγ expression. The method of the present invention comprises administering a subject in need thereof an effective amount of Lactobacillus gasseri (L. gasseri) PM-A0005.
The details of one or more embodiments of the present invention are set forth in the description below. Other features or advantages of the present invention will be apparent from the following detailed description of several embodiments and from the appended claims.
The present invention is further illustrated by reference to the accompanying drawings, in which:
Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art in the field of this invention. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.
As used herein, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly indicates otherwise. For example, “an element” means one element or more elements.
According to the invention, a method for enhancing PPARγ expression is provided, which comprises administrating a subject in need thereof an effective amount of Lactobacillus gasseri (L. gasseri) PM-A0005.
The Lactobacillus gasseri PM-A0005 was deposited under Budapest Treaty in the China Center for Type Culture Collection (CCTCC), China with Deposit No. M 207039, and was first disclosed to be effective in anti-allergy in U.S. Pat. No. 8,021,868 B2 (filed on Nov. 8, 2007).
As used herein, the term “subject” refers to an animal or a human being.
As used herein, the term “effective amount” refers to an amount effective in enhancing the PPARγ expression of a subject by administered either L. gasseri PM-A0005 alone or in combination with another material resulting in the same activity. As commonly known in the art, the effective amount may vary according to the particular active ingredient used, the mode of administration, and the age, size, and condition of the subject to be treated.
In one embodiment of the present invention, the effective amount of L. gasseri PM-A0005 administered to a subject is preferably between 1×108 CFU/kg/day to 1×109 CFU/kg/day of the body weight of the subject, preferably between 5×108 CFU/kg/day to 6×108 CFU/kg/day of the body weight of the subject.
In one preferred embodiment of the present invention, the effective amount is about 5.5×108 CFU/kg/day of the body weight of the subject.
According to one preferred embodiment of the present invention, the composition may be orally administered to a subject at an effective amount to enhance PPARγ expression in the subject.
According to the present invention, the L. gasseri PM-A0005 may be prepared in a composition. In one example of the invention, the composition is a pharmaceutical composition.
The composition or pharmaceutical composition according to the invention can be prepared in any suitable form. For example, two suitable forms are a solid form suitable for oral administration, e.g. pills, capsules, granules, tablets, and powders, or in a liquid form, e.g. drink, syrups, and suspension. The composition of the invention may be combined with one or more vectors or excipients, or supplemented with surfactants, lytic agents, stabilizer, emulsifiers, concentrates, sweeteners, or preservatives.
According to another embodiment of the present invention, the composition may be in a form of food. The food composition includes but is not limited to milk, fermented milk, drink, sports beverage, nutrition additive, dietary supplement, candy, or gelatin.
It is found in one example of the present invention, L. gasseri PM-A0005 or the composition comprising the strain can increase the PPARγ expression in the lung after administration of the composition to the subject. In particular, the composition can increase the PPARγ expression in the lung draining lymph node of the subject.
It is also found in another example of the invention, L. gasseri PM-A0005 or the composition comprising the strain can increase the PPARγ expression in the gut of a subject. In particular, the composition can increase the PPARγ expression in the mesenteric lymph node of the subject.
The present invention is further illustrated by the following examples, which are provided for the purpose of demonstration rather than limitation.
BALB/cBYJ mice were obtained from the Laboratory Animal Center of the College of Medicine, National Cheng Kung University. C57BL/6JNarl mice were obtained from National Laboratory Animal Center. Both BALB/cBYJ and C57BL/6JNarl mice, as well as PPARγ P465L mutant mice with half PPARγ expression rate (Tsai, Y. S. et al., J Clin Invest (2004) 114, 240-249) were female and age 6 to 8 weeks. All experimental animal care and treatment followed the guidelines set up by the National Institutes of Health Guide for the Care and Use of Laboratory. Dermatophagoides pteronyssinus (Der p) extract (1 g lyophilized whole body extract in ether; Allergon, Engelholm, Sweden) was dissolved in pyogenic-free isotonic saline, filtered through a 0.22-mm filter, and stored at 27° C. before use. LPS concentration of the Der p preparations was <0.96 EU/mg of Der p (limulus amebocyte lysate test, E-Toxate; Sigma-Aldrich, St Louis, Mo.).
A freeze-dried powder of L. gasseri PM-A0005 at concentration of 1.04×1011 CFU/g was dissolved in pyogenic-free isotonic saline to the concentrations of 5×107 CFU/ml and 5×109 CFU/ml, respectively, and store at −80° C. before use.
Mice were fed daily with 200 μl of normal saline (control group), 200 μl of L. gasseri PM-A0005 at 5×107 CFU/ml (low dosage group), or 200 μl of L. gasseri PM-A0005 at 5×109 CFU/ml (high dosage group) for two weeks before the experiment until day 13 (except day 0, day 7 and day 14 for mite allergen sensitization), mice were sensitized by subcutaneously injection at tail with a mixture of equal amount of Der p extract at concentration of 1.6 mg/ml and incomplete Freund adjuvant at day 0 and day 7. At day 14, mice were intratracheally challenged with 50 μg Der p extract after anesthetization and subsequently sacrificed at day 17 after airway resistance measurement at day 16.
Mite allergen sensitization model in mice was the same as described above, except that the mice were administered with PPARγ agonist or antagonist at day 12 to day 15. Rosiglitazone (PPARγ agonist) was dissolved in DMSO followed by diluted to 5 mg/ml with isotonic saline, then provided to mice in an amount of 5 mg/Kg. On the other hand, GW9662 (PPARγ antagonist) was dissolved in DMSO followed by diluted to 5 mg/ml with isotonic saline, then delivered to the mice by intratracheal injection in an amount of 5 mg/Kg. The mice were sacrificed at day 17 after airway resistance measurement at day 16.
PPARγ mutation mice or normal mice (C57BL/65Narl) were anesthetized with anesthetic (Zoletil 50 and Rompom in the ratio of 5:1) by intraperitoneal injection, followed by intranasally administered 10 μg of Der p extract daily for 11 days. The mice were sacrificed at day 14 after airway resistance measurement at day 13.
Mite allergen sensitization model in mice was the same as described above, except that the mice were administered daily with 109 CFU of L. gasseri PM-A0005 from 2 weeks of the day before mite allergen sensitization. Mice were evaluated with airway resistance measurement at day 13 and sacrificed at day 14.
The airway resistance of mice was measured by a single-chamber, unrestrained whole-body plethysmograph (Buxco Electronics, Inc., Troy, N.Y.) before they were euthanized. Airway resistance was expressed as enhanced pause (Penh). Different dosages of methacholine dissolved in PBS (6.25 mg/ml, 12.5 mg/ml, 25 mg/ml, and 50 mg/ml) were administered by spray for 3 minutes, and Penh values were measured over the period of the subsequent 3 minutes.
Total lung draining lymph node and mesenteric lymph nodes RNA extraction and isolation were performed using a Qiagen RNAeasy Mini kit according to manufacturer's instructions (Qiagen, Valencia, Calif.). RNA purity and quality were analyzed by Agilent Bioanalyzer 2100 scan (Agilent, Santa Clara, Calif.). Total RNA were amplified and labeled with Cy3 during in vitro transcription. 2 μg Cy3-labeled cRNA was incubated with fragmentation buffer at 60° C. for 30 minutes to obtain nucleotide fragments average from 50 to 100 and then hybridized with Affymetrix mouse 430 2.0 chips (Affymetrix, Santa Clara, Calif.) at 60° C. for 17 hours. Signal intensities and detection cells were extracted using dChip (v. 2006). Signal intensities of experimental groups were normalized and screened in comparison with positive control group to obtain genes with expression levels over 2 fold change in the low dosage or high dosage group, which were subsequently analyzed with Ingenuity Pathway Analysis database. In addition, common genes with expression levels 2 fold higher than the control group in the low dosage group but lower than control group in the high dosage group were selected for clustering analysis. Clustering analysis was also performed on common genes with expression levels that were 2 fold higher than the control group in the high dosage group but lower than control group in the low dosage group.
Effects on physiological health conditions of mice after feeding low dosage (1×107 CFU) or high dosage (1×109 CFU) of L. gasseri PM-A0005 were evaluated. As shown in
A. Lung Draining Lymph Node Gene Expression
Microarray analysis results showed that in the low dosage group, there were 682 genes with expression levels 2 fold higher than the positive control group. Clustering analysis was performed on these 682 genes with Ingenuity Pathway Analysis (IPA) database and the results demonstrated that these genes involve lipid metabolism and molecular transport pathway. In the high dosage group, there were 643 genes with expression levels 2 fold higher than positive control group, and clustering analysis demonstrated that these genes involve tissue morphology and development and function of skeletal and muscle system. 349 genes were identified in both the low dosage and high dosage group. In the low dosage group, 202 genes were identified as expression levels 2 fold lower than positive control group, and 249 genes were identified in the high dosage group, wherein 148 genes existed in both groups. Those analysis results demonstrated that gene expression patterns between low dosage group and high dosage group have no significant difference.
B. Mesenteric Lymph Node Gene Expression
Microarray analysis results showed that in the low dosage group, there were 765 genes with expression levels 2 fold higher than the positive control group. IPA results were similar with those of lung draining lymph node gene expression and demonstrated that these genes involve mainly lipid metabolism and molecular transport pathway. In the high dosage group, there were 391 genes with expression levels 2 fold higher than positive control group, and clustering analysis demonstrated that these genes involve apoptosis and cell cycle. 58 genes were existed in both the low dosage and high dosage group. In the low dosage group, 1275 genes were identified with expression levels 2 fold lower than the positive control group, and 449 genes were identified in the high dosage group, wherein 52 genes existed in both groups.
Microarray analysis results demonstrated that the administration of L. gasseri PM-A0005 induced expression level variation in lipid metabolism related genes, for example, PPARγ. Real-Time PCR was conducted to confirm the gene expression pattern was identical to the microarray analysis results. As shown in
To evaluate if the administration of L. gasseri PM-A0005 in allergic asthma mice could promote lung PPARγ expression, lung sections from naive group, positive control group and low dosage group (1×107 CFU) were stained with immunohistochemistry staining, and PPARγ expression levels were quantified. Analysis results revealed that PPARγ expression level in lung tissue of mite allergen sensitized mice was significant lower than that in normal control group, but administration of 1×107 CFU L. gasseri PM-A0005 daily could increase PPARγ expression level, which was significant higher than that in normal control group (
A single-chamber, unrestrained whole-body plethysmograph was used for measuring airway resistance of mice, expressed as enhanced pause (Penh) value. Higher Penh value refers to higher airway resistance, i.e. hyperresponsiveness. The analysis results showed that in the positive control group (mice sensitized with mite allergen), Penh value increased with the elevation of methacholine concentration, but administration of different dosages of L. gasseri PM-A0005 could significantly reduce mice airway hyperresponsiveness (
As shown in
The experimental results revealed that administration of L. gasseri PM-A0005 could reduce airway hyperresponsiveness in wild type mice, but not in the PPARγ P465L mutation mice. Penh value increased with the elevation of methacholine concentration, demonstrating that L. gasseri PM-A0005 could not reduce airway hyperresponsiveness in PPARγ P465L mutation mice.
It will be understood by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is therefore understood that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 101122060 | Jun 2012 | TW | national |
